Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK
- Conditions
- Myoclonus Epilepsies, Progressive
- Interventions
- Drug: AUT00201Drug: Placebo
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Autifony Therapeutics Limited
- Target Recruit Count
- 6
- Registration Number
- NCT05873062
- Locations
- πΊπΈ
University of Pennsylvania, Penn Epilepsy Center, Philadelphia, Pennsylvania, United States
Safety, Blood Levels and Effects of AUT00201
- Conditions
- Healthy Volunteer
- Interventions
- Drug: AUT00201Drug: Placebo
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2021-01-13
- Lead Sponsor
- Autifony Therapeutics Limited
- Target Recruit Count
- 80
- Registration Number
- NCT04158453
- Locations
- π¬π§
Hammersmith Medicines Research, London, United Kingdom
Safety, Tolerability and Pharmacokinetics of AUT00206 in Patients With Schizophrenia, and Also Explores the Effects of AUT00206 on Relevant Central Biomarkers.
- Conditions
- Schizophrenia
- Interventions
- Drug: AUT00206Drug: Placebo
- First Posted Date
- 2017-05-24
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Autifony Therapeutics Limited
- Target Recruit Count
- 24
- Registration Number
- NCT03164876
- Locations
- π¬π§
King's College London Institute of Psychiatry, Psychology and Neuroscience (IoPPN), London, United Kingdom
A Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Males
- Conditions
- Schizophrenia
- Interventions
- Drug: High dose AUT00206 2000 mgDrug: Low dose AUT00206 800mgDrug: PlaceboDrug: KetamineOther: Saline
- First Posted Date
- 2016-10-17
- Last Posted Date
- 2017-11-27
- Lead Sponsor
- Autifony Therapeutics Limited
- Target Recruit Count
- 22
- Registration Number
- NCT02935725
- Locations
- π¬π§
University Of Manchester, London, United Kingdom
Evaluating Possible Improvement in Speech and Hearing Tests After 28 Days of Dosing of the Study Drug AUT00063 Compared to Placebo (QuicKfire)
- Conditions
- Hearing ImpairmentHearing Loss
- Interventions
- Drug: AUT00063Drug: Placebo
- First Posted Date
- 2016-07-14
- Last Posted Date
- 2017-05-24
- Lead Sponsor
- Autifony Therapeutics Limited
- Target Recruit Count
- 15
- Registration Number
- NCT02832128
- Locations
- π¬π§
Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
π¬π§Royal National Throat, Nose and Ear Hospital, London, United Kingdom
π¬π§Manchester Royal Infirmary, Manchester, United Kingdom
Safety, Blood Levels and Effects of AUT00206
- Conditions
- Schizophrenia
- First Posted Date
- 2015-10-28
- Last Posted Date
- 2016-10-14
- Lead Sponsor
- Autifony Therapeutics Limited
- Registration Number
- NCT02589262
- Locations
- π¬π§
Hammersmith Medicines Research, London, United Kingdom
Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss
- Conditions
- Age-Related Hearing Loss
- Interventions
- Drug: AUT00063Drug: Placebo
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- Autifony Therapeutics Limited
- Target Recruit Count
- 78
- Registration Number
- NCT02345031
- Locations
- πΊπΈ
The University of Mississippi Medical Center, Jackson, Mississippi, United States
πΊπΈQPS MRA (Miami Research Associates), Miami, Florida, United States
πΊπΈSacramento ENT, Sacramento, California, United States
Evaluating Possible Improvement in Tinnitus Severity After 28 Days Dosing of the Study Drug AUT00063 Compared to Placebo
- Conditions
- Tinnitus, Subjective
- Interventions
- Drug: AUT00063Drug: Placebo
- First Posted Date
- 2014-12-12
- Last Posted Date
- 2016-03-31
- Lead Sponsor
- Autifony Therapeutics Limited
- Target Recruit Count
- 91
- Registration Number
- NCT02315508
- Locations
- π¬π§
Bristol Royal Infirmary, Bristol, United Kingdom
π¬π§Cambridge University Hospitals NHS Trust, Cambridge, United Kingdom
π¬π§Freeman Hospital, Newcastle, United Kingdom